Shrenika Reddy, MD
Endocrinology, Diabetes & Metabolism · Festus, MONPI 1801258207
Payments from drug & device makers
Across 499 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$876
- Mannkind Corporation$753
- Medtronic$639
- Corcept Therapeutics$633
- Lilly USA, LLC$581
- Amgen$566
- plus $5K from 35 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $876 |
| Mannkind Corporation | 48 | $753 |
| Medtronic | 23 | $639 |
| Corcept Therapeutics | 25 | $633 |
| Lilly USA, LLC | 36 | $581 |
| Amgen(2 entities) | 32 | $566 |
| Boehringer Ingelheim | 26 | $486 |
| Dexcom, Inc. | 57 | $393 |
| Novartis | 20 | $373 |
| Sanofi-aventis U.S. LLC | 19 | $350 |
| Bayer | 13 | $326 |
| Xeris Pharmaceuticals, Inc. | 15 | $283 |
| Insulet Corporation | 8 | $228 |
| Recordati_rare_diseases_inc. | 7 | $225 |
| Radius Health, Inc. | 9 | $223 |
| Nevro Corp. | 7 | $218 |
| Abbott | 8 | $164 |
| AstraZeneca | 7 | $132 |
| Amphastar Pharmaceuticals, Inc. | 7 | $129 |
| UCB, Inc. | 6 | $120 |
| Antares Pharma, Inc. | 7 | $118 |
| Tandem Diabetes Care, Inc. | 5 | $110 |
| Ascendis Pharma Endocrinology Inc | 4 | $90 |
| Sequel Med Tech, LLC | 4 | $83 |
| BETA Bionics, Inc. | 5 | $83 |
| Kyowa Kirin, Inc. | 3 | $71 |
| Averitas Pharma Inc. | 3 | $64 |
| Johnson & Johnson | 3 | $55 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 3 | $48 |
| AbbVie | 2 | $44 |
| Madrigal Pharmaceuticals | 2 | $41 |
| Merck | 2 | $36 |
| Globus Medical | 2 | $36 |
| Ascensia Diabetes Care US Inc. | 2 | $32 |
| Halozyme Inc | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Echosens North America, Inc. | 1 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
How this compares
$8,814 in reported general payments places this provider in the 75th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Festus
- Ralph DudaSpringfield$3M
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Gregory LedgerSpringfield$690K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Julie SilversteinSaint Louis$536K
- Ralph OiknineChesterfield$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.